In Vitro Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii

被引:61
作者
Hagihara, Mao [1 ,2 ]
Housman, Seth T. [1 ]
Nicolau, David P. [1 ]
Kuti, Joseph L. [1 ]
机构
[1] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06115 USA
[2] Aichi Med Univ, Nagakute, Aichi, Japan
关键词
CRITICALLY-ILL PATIENTS; TIME-KILL; POPULATION PHARMACOKINETICS; ANTIMICROBIAL AGENTS; MULTIDRUG-RESISTANCE; PNEUMONIA MODEL; UNITED-STATES; COLISTIN; INFECTIONS; MANAGEMENT;
D O I
10.1128/AAC.01624-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Carbapenem-resistant Acinetobacter baumannii is increasing in prevalence. Polymyxin B and tigecycline are among the most active antibiotics used against this pathogen in vitro. Past in vitro studies, however, neglected the importance of simulating exposures observed in humans to determine their antibacterial effects. In this study, four carbapenem-resistant A. baumannii isolates were evaluated using an in vitro pharmacodynamic model. Free-drug exposures using 1 mg/kg of body weight of polymyxin B every 12 h (q12h), 100 and 200 mg tigecycline q12h, and the combination of these regimens were simulated. The microbiological responses to these treatments were measured by the change in log(10) CFU/ml over 24 h and the area under the bacterial killing and regrowth curve (AUBC). Resistance was assessed by a population analysis profile (PAP) conducted after 24 h of treatment. Polymyxin B achieved a reduction on the order of -2.05 +/- 0.68 log(10) CFU/ml against these A. baumannii isolates, while all isolates grew to control levels with tigecycline monotherapy. Combination therapy with polymyxin B plus 200 mg tigecycline q12h achieved a greater reduction in bacterial density than did therapy with polymyxin B alone (-3.31 +/- 0.71 versus -2.05 +/- 0.68 log(10) CFU/ml, P < 0.001) but not significantly different than combination therapy with 100 mg tigecycline q12h (-2.45 +/- 1.00 log(10) CFU/ml, P = 0.370). Likewise, combination therapy with polymyxin B plus 200 mg tigecycline q12h significantly reduced the AUBC compared to that with polymyxin B alone (62.8 +/- 8.9 versus 79.4 +/- 10.5 log(10) CFU/ml, P < 0.05). No changes in the PAP from baseline were observed for either antibiotic alone. In this study, combination therapy with simulated exposures of polymyxin B and tigecycline at an aggressive dose of 200 mg q12h produced synergistic or additive effects on humans against these multidrug-resistant A. baumannii strains.
引用
收藏
页码:874 / 879
页数:6
相关论文
共 38 条
  • [1] Molecular Epidemiology of Carbapenem-Nonsusceptible Acinetobacter baumannii in the United States
    Adams-Haduch, Jennifer M.
    Onuoha, Ezenwa O.
    Bogdanovich, Tatiana
    Tian, Guo-Bao
    Marschall, Jonas
    Urban, Carl M.
    Spellberg, Brad J.
    Rhee, Diane
    Halstead, Diane C.
    Pasculle, Anthony W.
    Doi, Yohei
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (11) : 3849 - 3854
  • [2] Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa
    Bonomo, Robert A.
    Szabo, Dora
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 : S49 - S56
  • [3] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
    Boucher, Helen W.
    Talbot, George H.
    Bradley, John S.
    Edwards, John E., Jr.
    Gilbert, David
    Rice, Louis B.
    Scheld, Michael
    Spellberg, Brad
    Bartlett, John
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) : 1 - 12
  • [4] Clinical and Laboratory Standards Institute, 2007, M7A7 CLSI
  • [5] fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models
    Dudhani, Rajesh V.
    Turnidge, John D.
    Nation, Roger L.
    Li, Jian
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (09) : 1984 - 1990
  • [6] Impact of Carbapenem Resistance and Receipt of Active Antimicrobial Therapy on Clinical Outcomes of Acinetobacter baumannii Bloodstream Infections
    Esterly, John S.
    Griffith, Milena
    Qi, Chao
    Malczynski, Michael
    Postelnick, Michael J.
    Scheetz, Marc H.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (10) : 4844 - 4849
  • [7] Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
    Falagas, ME
    Kasiakou, SK
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) : 1333 - 1341
  • [8] Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: Action of ciprofloxacin against Escherichia coli in an in vitro dynamic model
    Firsov, AA
    Vostrov, SN
    Shevchenko, AA
    Cornaglia, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1281 - 1287
  • [9] Multiresistant Acinetobacter baumannii infections: epidemiology and management
    Garnacho-Montero, Jose
    Amaya-Villar, Rosario
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2010, 23 (04) : 332 - 339
  • [10] Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)
    Henwood, CJ
    Gatward, T
    Warner, M
    James, D
    Stockdale, MW
    Spence, RP
    Towner, KJ
    Livermore, DM
    Woodford, N
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) : 479 - 487